-
Jingfeng Pharmaceutical Subsidiary Received Notification of Approval of Bingzhishangtong Aerosol Drug Supplement Application
Time of Update: 2021-11-05
The main function of the drug is to clear away heat, detoxify and cool blood, promote blood circulation, remove blood stasis and relieve pain .
The benchmark product of Bingzhishangtong aerosol in the current market is Yunnan Baiyao aerosol .
-
A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.
Time of Update: 2021-11-05
They are: Hengrui SHR-1819 injection for the treatment of atopic dermatitis; Luye Pharma’s LPM3770164 sustained-release tablets for use For the treatment of tardive dyskinesia and Huntington's disease; Cody Bio Finasteride spray, topical treatment of mild to moderate male pattern baldness (androgenic alopecia) in 18-41-year-old males, promote hair growth and prevent Hair loss continues; Tianguangshi Bio-recombinant humanized monoclonal antibody MIL62 injection treats systemic myasthenia gravis .
-
Can the PD-(L)1 double antibody surpass the PD-(L)1 monoclonal antibody?
Time of Update: 2021-11-05
6% better than K drug historical data in the registered phase II clinical treatment of patients with recurrent or metastatic cervical squamous cell carcinoma, and reached 47.
-
Shanghai Pharmaceuticals: Caffeine Citrate Injection was approved for production
Time of Update: 2021-11-05
On September 13, Shanghai Pharmaceuticals issued an announcement stating that the caffeine citrate injection of its subsidiary, Shanghai Hefeng, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production .
-
Hengrui introduces the third-generation anti-CD20 monoclonal antibody of Tianguangshi Biology for a US$30 million equity investment
Time of Update: 2021-11-05
The two parties reached an agreement, and Tianguangshi Biotech granted Hengrui Pharmaceutical the exclusive commercialization rights for the third-generation anti-CD20 antibody MIL62 in the Greater China region (including Mainland China, Taiwan, Hong Kong, and Macau).
-
Patent layout of the world's first Duchenne muscular dystrophy new drug eteplirsen
Time of Update: 2021-11-05
Figure 2 Eteplirsen branched chain fragment structureIn addition, the patents involved in the nucleic acid modification method phosphorodiamide morpholino oligomer (PMO) are shown in Table 2.
-
Zhengda Tianqing, Osaikang... grab 1.5 billion injections!
Time of Update: 2021-11-05
A few days ago, the official website of the State Food and Drug Administration showed that Liaoning Haisco Pharmaceutical's Palonosetron Hydrochloride Injection was approved as a supplementary application.
According to data from Meinenet, the sales of Palonosetron Hydrochloride Injection in China's public medical institutions in 2020 will exceed 1.
-
Next-generation LPA1 antagonist Bristol-Myers Squibb Class 1 new drug approved for clinical use in China
Time of Update: 2021-11-05
ArticleMedicine GuanlanAccording to the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, the Class 1 new drug BMS-986278-01, declared by Bristol-Myers Squibb Company (BMS), has been approved for two clinical trials in China, with special indications.
-
Sihuan Pharmaceutical "disrupts" 3.5 billion cardiovascular products, Renfu and Dongyang Pharmaceutical, 5 companies report for production
Time of Update: 2021-11-05
Among them, Metoprolol Succinate Sustained Release Tablets There are 4 manufacturing companies, Hainan Huayitaikang Pharmaceutical, Hefei Heyuan Pharmaceutical, and Foshan Derek Pharmaceuticals, all of which have been approved for imitation of category 4, which are deemed to have been reviewed .
-
Baili Pharmaceutical's EGFR/HER3 double antibody was approved for two clinical trials
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsThe latest announcement by the Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China shows that the Class 1 new drug SI-B001 bispecific a
-
1 billion cephalosporin injection Haisco overtakes the first review
Time of Update: 2021-11-05
0 Chinese Drug Evaluation DatabaseAccording to data from Mi Nei. com, as of now, Haisco and its subsidiaries have reviewed/deemedly reviewed 19 products (including the approved products this time), of which 10 are injections .
-
$2 billion psoriasis oral drug first imitation arrow on the string, monoclonal antibody cuts in price and enters medical insurance to compete for the track
Time of Update: 2021-11-05
Under the general trend of entering the national medical insurance catalogue and actively reducing prices of foreign products to compete for the market, monoclonal antibody drugs for the treatment of psoriasis will further expand in the Chinese market .
-
Bristol-Myers Squibb’s PD-1 Inhibitor’s New Indication Application for Listing Enters "Under Approval"
Time of Update: 2021-11-05
According to the announcement of the National Food and Drug Administration (NMPA) of China, Bristol-Myers Squibb Company (BMS) Nivolumab Injection (Odivo)’s new indication listing application status has been updated to “under review”, which means The drug is expected to usher in new indications in China in the near future .
-
The 8th Merck Keytruda new indication is expected to be approved in China in the near future
Time of Update: 2021-11-05
Transfer from | Pharmaceutical Mission HillsAccording to the announcement of the China National Medical Products Administration (NMPA), the listing application for new indications of Merck’s (MSD) PD-1 inhibitor pembrolizumab injection (Keytruda, pembrolizumab) has been updated to: Under review .
Retrieved June 29, 2020, from https:// first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer[3] China Drug Clinical Trial Registration and Information Disclosure Platform.
-
Lose again!
Time of Update: 2021-11-05
This study aims to evaluate the efficacy and safety of Merck's TGF-β/PD-L1 bifunctional fusion protein bintrafusp alfa combined with gemcitabine and cisplatin in the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) .
-
These 22 pharmaceutical companies are bright!
Time of Update: 2021-11-05
List of national technological innovation demonstration pharmaceutical companies that have passed the review and evaluation in 2021CSPC: Two-wheel drive of innovation and internationalizationCSPC: Two-wheel drive of innovation and internationalizationCSPC's revenue and R&D investment (unit: 100 million yuan)CSPC is a national-level innovative enterprise integrating R&D, production and sales of innovative drugs .
-
Borui Biologics ``Infliximab'' biosimilar drug approved for marketing
Time of Update: 2021-11-05
Text|Pharmaceutical Mission HillsOn September 28, the National Food and Drug Administration (NMPA) announced that the infliximab for injection declared by Hisun Biologics, a wholly-owned subsidiary of Zhejiang Borui Biopharmaceutical Co.
Retrieved Sep 28, 2021, from https:// Hisun Biologics Infliximab for injection (proposed trade name: Ambaite®) was declared and listed.
-
"730 Heights" of generic drug patents
Time of Update: 2021-11-05
Although China's patent information registration platform cannot register crystal patents, after generic drugs are marketed, the original drugs can still be sued for this patent .
-
New HER2-positive breast cancer drug!
Time of Update: 2021-11-05
The data showed that: HER2 positive in previous treatments with trastuzumab and taxane In patients with unresectable and/or metastatic breast cancer, Enhertu has a significantly better efficacy than Kadcyla, with high and consistent significant benefits observed in multiple efficacy endpoints and key subgroups .
-
AbbVie's IL-23 inhibitor is expected to gain the second indication with EU CHMP support
Time of Update: 2021-11-05
Reference materials:[1] AbbVie Receives CHMP Positive Opinion for Risankizumab (Skyrizi®) for the Treatment of Adults with Active Psoriatic Arthritis in the European Union (EU).
com/news/ press-releases/abbvie-receives-chmp-positive-opinion-for-risankizumab-skyrizi-for-treatment-adults-with-active-psoriatic-arthritis-in-european-union-eu.
